论文部分内容阅读
为探讨麻疹、风疹减毒活疫苗联合免疫的可行性，于1997年4～12月随机选择了本市342名8月龄婴儿进行了观察．所有入选婴儿被随机分成3组：第1组105人，皮下接种BRD－Ⅱ株风疹疫苗；第2组105人，分别在左、右上臂同时皮下接种BRD—Ⅱ株风疹疫苗和沪191株冻干麻疹疫苗；第3组132人，皮下接种沪191株冻干麻疹疫苗．在免疫前，第1组与第2组的风疹血凝抑制（HI）抗体阳性率均为2．86％，几何平均滴度（GMT）均为1：1．06；第2组与第3组的麻疹HI抗体阳性率分别为2．86％和5.30％，GMT分别为1：1.02和1：1.60.免疫后1个月，第1组与第2组的风疹HI抗体阳性率分别为98.10％和99．05％，GMT分别为1：144.15和1：148.99，两者的差异无显著的统计学意义；第2组与第3组的麻疹HI抗体阳性率分别为99.05％和97.73％，GMT分别为1：35．10和1：32．85，两者的差异亦无显著的统计学意义．所有免疫的儿童均未发现局部和全身反应．结果表明：麻疹、风疹减毒活疫苗联合免疫可产生与常规免疫相同的免疫应答，风疹疫苗初免月龄定于8月龄与麻疹疫苗联合免疫是可行的．
In order to explore the feasibility of measles and rubella attenuated live vaccine combined immunization, we randomly selected 342 8-month-old infants from April to December 1997 in our city. All the selected infants were randomly divided into 3 groups: group 1 of 105 people was inoculated with BRD-Ⅱ strain of rubella vaccine subcutaneously; group 2 of 105 people were vaccinated with BRD-Ⅱ strain of rubella vaccine and strain 191 Dry measles vaccine; Group 3 132 people were vaccinated subcutaneously Shanghai 191 freeze-dried measles vaccine. Before immunization, the positive rates of rubella hemagglutination inhibition (HI) antibodies in group 1 and group 2 were both 2.86%, the geometric mean titers (GMTs) were 1: 1.06, while those in group 2 and group 3 The positive rates of HI antibody of measles group were 2.86% and 5.30% respectively, GMT was 1: 1.02 and 1: 1.60, respectively.The positive rates of rubella HI antibody of group 1 and group 2 were 98.10 % And 99.05%, GMT were 1: 144.15 and 1: 148.99, respectively, with no significant difference between the two groups. The positive rates of measles HI antibodies in group 2 and group 3 were 99.05% and 97.73% GMT were 1: 35.10 and 1: 32.85, the difference between the two nor significant statistical significance. All immunized children found no local and systemic reactions. The results showed that combined immunization with live attenuated measles and rubella vaccine produced the same immune response as conventional immunization. It is feasible to combine immunization with measles vaccine at 8 months of age.